Immunity claims are next on FTC’s radar, says legal expert

Immunity is likely to be the next major focus for the US Federal Trade Commission (FTC) as it closes its fist over fraudulent dietary supplement products, suggests a food and drug lawyer.

The issue – which is already on the agency’s hit list – will most certainly be in the spotlight during the weeks ahead as the potential swine flu epidemic has already triggered the promotion of supplements purporting to protect against the virus, says Marc Ullman, partner at Ullman, Shapiro & Ullman.

“Any company that engages in that kind of marketing is inviting very swift and very serious enforcement action (…) I think FTC and FDA will be all over this,” he tells Lorraine Heller in this podcast.

Explore related questions

Beta

Ingredient firms beware

In addition, Ullman predicts that a recent FTC clamp-down against a weight loss ingredient supplier could be heralding a change of tides.

“I suspect that this may the first in a series of cases that we see from FTC directed at ingredients suppliers.”